Bamco Inc. NY grew its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 108.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 183,263 shares of the biopharmaceutical company’s stock after buying an additional 95,140 shares during the quarter. Bamco Inc. NY owned 0.39% of SAGE Therapeutics worth $29,518,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. California Public Employees Retirement System grew its stake in SAGE Therapeutics by 58.7% in the third quarter. California Public Employees Retirement System now owns 12,699 shares of the biopharmaceutical company’s stock worth $791,000 after purchasing an additional 4,699 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in SAGE Therapeutics by 25.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 189,230 shares of the biopharmaceutical company’s stock worth $31,169,000 after purchasing an additional 38,204 shares in the last quarter. Legato Capital Management LLC bought a new position in SAGE Therapeutics in the fourth quarter worth approximately $441,000. Arthur M. Cohen & Associates LLC bought a new position in SAGE Therapeutics in the fourth quarter worth approximately $1,364,000. Finally, Fiduciary Trust Co. grew its stake in SAGE Therapeutics by 21.8% in the fourth quarter. Fiduciary Trust Co. now owns 19,111 shares of the biopharmaceutical company’s stock worth $3,148,000 after purchasing an additional 3,424 shares in the last quarter. 95.31% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director James M. Frates sold 7,000 shares of the stock in a transaction on Tuesday, May 8th. The stock was sold at an average price of $154.00, for a total transaction of $1,078,000.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at approximately $1,848,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steven M. Paul sold 58,139 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $172.00, for a total value of $9,999,908.00. Following the sale, the director now owns 632,712 shares of the company’s stock, valued at approximately $108,826,464. The disclosure for this sale can be found here. In the last quarter, insiders have sold 164,427 shares of company stock valued at $26,811,600. Company insiders own 6.10% of the company’s stock.
SAGE Therapeutics opened at $164.26 on Friday, Marketbeat Ratings reports. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of -23.17 and a beta of 3.05. SAGE Therapeutics Inc has a twelve month low of $59.57 and a twelve month high of $195.97.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the consensus estimate of ($1.84) by $0.16. During the same period in the previous year, the business posted ($1.52) EPS. equities analysts forecast that SAGE Therapeutics Inc will post -8.34 EPS for the current year.
Several research analysts recently issued reports on SAGE shares. BidaskClub cut SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Morgan Stanley began coverage on SAGE Therapeutics in a research note on Monday, February 26th. They issued an “overweight” rating and a $225.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $193.00 target price on shares of SAGE Therapeutics in a report on Friday, February 23rd. Cowen restated a “buy” rating and set a $202.00 target price on shares of SAGE Therapeutics in a report on Tuesday, March 20th. Finally, Canaccord Genuity restated a “buy” rating and set a $210.00 target price on shares of SAGE Therapeutics in a report on Monday, March 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $185.20.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.